Skip to main content

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today separately announced that in connection with the listing of American Depositary Shares ("ADSs") representing ordinary shares of nominal value of €0.01 each in the capital of the Company ("Ordinary Shares") on the Nasdaq Global Market ("Nasdaq"), the United States Securities and Exchange Commission has declared effective registration statements on Form F-1 and F-6 with respect to such securities, Nasdaq has approved the ADSs for listing, and ADSs will begin trading on such market under the symbol "PHAR" from tomorrow; Wednesday 23 December.

This announcement is intended to guide holders of Ordinary Shares, which are listed and admitted to trading on Euronext Amsterdam through the process of converting Ordinary Shares into ADSs, and to answer certain related frequently asked questions applicable to holders of Ordinary Shares.

In addition, to facilitate the initial conversions of Ordinary Shares into ADSs, the Depositary (JP Morgan Chase) has agreed to waive the conversion fees of US$5.00 per 100 ADSs that shareholders will incur from the Depositary for such conversion for the first four weeks following the listing.

For any further questions about the Ordinary Share to ADS exchange process, please contact the Company's ADS Depositary Bank, JPMorgan Chase Bank, N.A. (the “Depositary”) (see contact details below in the “Notes for Brokers section”).

Cookies: This website uses cookies Check the cookies page for more information Accept Decline